FDAsafety guidance83% confidence
Phase 1 IND Learning Resources
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to pediatric liver disease treatments.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Pediatrics · Cholestasis
- Sub-indication
- General
Related signal: Machine Learning Study Aims to Diagnose Cholestasis in Newborns Using Parent-Provided Images